Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus ENPRESSE 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus ENPRESSE 28.
CRYSELLE vs ENPRESSE-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive